Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)

January 2004
Cardiovascular Diabetology;2004, Vol. 3, p8
Academic Journal
Background: Hypertriglyceridemia in combination with low HDL cholesterol levels is a risk factor for cardiovascular disease. Our objective was to evaluate the efficacy of ciprofibrate for the treatment of this form of dyslipidemia and to identify factors associated with better treatment response. Methods: Multicenter, international, open-label study. Four hundred and thirty seven patients were included. The plasma lipid levels at inclusion were fasting triglyceride concentrations between 1.6-3.9 mM/l and HDL cholesterol ? 1.05 mM/l for women and ? 0.9 mM/l for men. The LDL cholesterol was below 4.2 mM/l. All patients received ciprofibrate 100 mg/d. Efficacy and safety parameters were assessed at baseline and at the end of the treatment. The primary efficacy parameter of the study was percentage change in triglycerides from baseline. Results: After 4 months, plasma triglyceride concentrations were decreased by 44% (p < 0.001). HDL cholesterol concentrations were increased by 10% (p < 0.001). Non-HDL cholesterol was decreased by 19%. A greater HDL cholesterol response was observed in lean patients (body mass index < 25 kg/m�) compared to the rest of the population (8.2 vs 19.7%, p < 0.001). In contrast, cases with excess body weight had a larger decrease in non-HDL cholesterol levels (-20.8 vs - 10.8%, p < 0.001). There were no significant complications resulting from treatment with ciprofibrate. Conclusions: Ciprofibrate is efficacious for the correction of hypertriglyceridemia / low HDL cholesterol. A greater decrease in non-HDL cholesterol was found among cases with excess body weight. The mechanism of action of ciprofibrate may be influenced by the pathophysiology of the disorder being treated.


Related Articles

  • dear reader. Blumenthal, Mark // HerbalGram;May-Jul2007, Issue 74, p6 

    The author reflects on a study conducted by Stanford University on the cholesterol-lowering effect of garlic. The study concluded that garlic did not have any effect on the patients with high cholesterol who participated in the study. The author is concerned that these findings may be misleading...

  • Anacetrapib: potential for the prevention and treatment of coronary heart disease. Steen, Dylan L.; Khera, Amit V.; Cannon, Christopher P. // Research Reports in Clinical Cardiology;2013, Vol. 4, p39 

    Despite major advances in cardiovascular care in recent decades, atherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Statins have been shown to reduce cardiovascular events by 25%-40% in a dose-dependent fashion; yet additional therapies are...

  • Transitioning from population to individualized preventive cardiology. Morris, Pamela B.; Wright, Richard F. // Research Reports in Clinical Cardiology;2013, Vol. 4, p55 

    There is an ongoing discussion about whether treatment strategies developed from population based studies lead to inappropriate care of individual patients. This article proposes that despite management of lipid-lowering therapy to established low-density lipoprotein cholesterol (LDL-C) goals,...

  • Specialized focus. Hewitt, Allison // Pharmaceutical Executive;Nov97, Vol. 17 Issue 11, p104 

    Focuses on the information contained in the report entitled `The U.S. and Worldwide Markets for Interventional Vascular Devices and Therapies,' released by New Medicine. Worldwide market for the vascular devices; Information on estimate and analysis of procedure and diagnostic tests.

  • Fish oil helps angioplasty. Levin, Arthur A. // HealthFacts;Apr92, Vol. 17 Issue 155, p2 

    Comments on a new study in `Circulation' which finds that people who take fish oil supplements before and after angioplasty increase their likelihood of benefiting from the procedure. Angioplasty and the treatment of angina; Details of the procedure; Previous studies which investigated the value...

  • Many generalists overestimate cardiovascular risk and the benefits of therapy.  // Modern Medicine;Jun96, Vol. 64 Issue 6, p48 

    Presents the abstract of the study entitled `Differences in Generalists' and Cardiologists' Perceptions of Cardiovascular Risk and the Outcomes of Preventive Therapy in Cardiovascular Disease,' by Friedmann, Brett et al published in the February 15, 1996 issue of the `Annals of Internal...

  • Thromboembolism patients at risk are under-protected.  // RN;Mar92, Vol. 55 Issue 3, p115 

    States that although venous thromboembolism can often be prevented, prophylactic measures are too often ignored. Study; Use of low-dose heparin, intermittent calf compression, warfarin and more; Details.

  • How should heparin be administered to combat DVT?  // RN;Dec92, Vol. 55 Issue 12, p81 

    Cites a report in the `Annals of Internal Medicine' which shows that subcutaneous heparin injections are more effective than continuous intra venous infusion for treating deep vein thrombosis. Lower risk of major hemorrhage.

  • ACE inhibitor may improve survival after MI. Rodman, Morton J. // RN;Dec92, Vol. 55 Issue 12, p83 

    Cites the findings of a multi-center study published in the `New English Journal of Medicine' which indicates that long-term administration of the ACE inhibitor captopril (Capoten) appears to improve survival in patients with asymptomatic left ventricular dysfunction. Reduction of risk of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics